KREBS BIOCHEMICALS & INDUSTRIES LIMITED Krebs Biochemicals & Industries Limited Share Price NSE India S.E.
Equities
KREBSBIO
INE268B01013
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 70.95 INR | -0.49% |
|
-2.78% | -9.44% |
| Sales 2022 | 587M 7.04M 557M | Sales 2023 | 521M 6.26M 495M | Capitalization | 1.22B 14.59M 1.15B |
|---|---|---|---|---|---|
| Net income 2022 | -445M -5.34M -422M | Net income 2023 | -247M -2.96M -234M | EV / Sales 2022 | 7.71 x |
| Net Debt 2022 | 1.43B 17.16M 1.36B | Net Debt 2023 | 1.83B 21.99M 1.74B | EV / Sales 2023 | 5.85 x |
| P/E ratio 2022 |
-6.94
x | P/E ratio 2023 |
-4.92
x | Employees | 210 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 22.45% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.49% | ||
| 1 week | -2.78% | ||
| Current month | +14.44% | ||
| 1 month | +5.11% | ||
| 3 months | +11.73% | ||
| 6 months | -10.47% | ||
| Current year | -9.44% |
1 week
69.33
74.00
1 month
61.0080.20
Current year
60.3583.00
1 year
60.3593.95
3 years
50.65227.90
5 years
50.65227.90
10 years
50.65227.90
| Managers | Title | Age | Since |
|---|---|---|---|
Jitendra Shah
CEO | Chief Executive Officer | - | 08/11/21 |
| Founder | 74 | 01/12/91 | |
Ritesh Jain
DFI | Director of Finance/CFO | - | 02/02/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 67 | 25/09/00 | |
| Founder | 74 | 01/12/91 | |
Avinash Ravi
BRD | Director/Board Member | 45 | 31/12/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/06/24 | 70.95 | -0.49% | 15,300 |
| 27/06/24 | 71.3 | -0.11% | 13,335 |
| 26/06/24 | 71.38 | +0.98% | 28,351 |
| 25/06/24 | 70.69 | +0.26% | 25,840 |
| 24/06/24 | 70.51 | -1.14% | 16,785 |
Delayed Quote NSE India S.E., June 28, 2024 at 12:43 pm
More quotes
Krebs Biochemicals & Industries Ltd is an India-based company, which is engaged in the business of manufacture of active pharmaceutical ingredients. The Company manufactures bulk active pharmaceutical ingredients, pharmaceutical intermediates, fine chemicals, nutraceuticals utilizing two revenue streams: contract manufacturing for large pharmaceutical and multinational companies, and development of its products for sale in global markets. Its products include Androstenedione, Lovastatin, and Simvastatin. The Companyâs pilot or research and development stages products are Amlodipine, Cetirizine, Orlistat, Serratiopepetidase, Telmisartan, and Phenylephrine. The Company has two manufacturing facilities one at Regadichelaka, Nellore District and another one at Kothapalli Village, Kasimkota Mandal, Visakhapatnam District, Andhra Pradesh, India.
Sector
Pharmaceuticals
Calendar
08/08/2024
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +20.76% | 43.59B | |
| +28.00% | 22.54B | |
| +20.25% | 15.73B | |
| +18.82% | 14.33B | |
| +55.83% | 12.75B | |
| -0.05% | 6.79B | |
| -12.70% | 6.48B | |
| -8.87% | 5.73B | |
| +14.65% | 5.67B |
- Stock Market
- Equities
- KREBSBIO Stock
- KREBSBIO Stock
